Suggested Remit: To appraise the clinical and cost effectiveness of luspatercept within its marketing authorisation for treating anaemia caused by myelodysplastic syndromes.
The company, Celgene UK, has informed NICE that they are unable to provide an evidence submission at this time and will work with us to reschedule. Therefore, we are suspending the appraisal whilst we consider the next steps. Therefore the discussion of this appraisal at the committee meeting in July 2020 has been cancelled.
 
Status Suspended
Process STA 2018
ID number 1550

Project Team

Project lead Jeremy Powell

Email enquiries

Evidence Review Group / Assessment Group School of Health and Related Research (ScHARR), University of Sheffield

Timeline

Key events during the development of the guidance:

Date Update
06 February 2020 Suspended. The company, Celgene UK, has informed NICE that they are unable to provide an evidence submission at this time and will work with us to reschedule. Therefore, we are suspending the appraisal whilst we consider the next steps. Therefore the discussion of this appraisal at the committee meeting in July 2020 has been cancelled.
07 November 2019 Invitation to participate
07 November 2019 In progress
28 May 2019 - 25 June 2019 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance